news
Pfizer completes acquisition of Anacor Pharmaceuticals
The Anacor acquisition adds crisaborole, a differentiated non-steroidal topical PDE4 inhibitor with anti-inflammatory properties, to Pfizer's pipeline...
List view / Grid view
Atopic Dermatitis
news
Dupilumab + TCS superior to TCS alone in treating atopic dermatitis
6 June 2016 | By Victoria White, Digital Content Producer
Sanofi and Regeneron have announced that a one-year Phase III study evaluating investigational dupilumab met its primary and key secondary endpoints.
news
Positive topline results from two Phase III dupilumab studies
1 April 2016 | By Victoria White
Sanofi and Regeneron have announced positive topline results from two placebo-controlled Phase III studies evaluating investigational dupilumab in adult patients with inadequately controlled moderate-to-severe atopic dermatitis (AD).
news
Positive top-line Phase IIa trial results for DS107 as a treatment for atopic dermatitis
7 January 2016 | By Nicholas Jackson
DS Biopharma has announced positive top-line Phase IIa trial results for DS107 as an oral treatment for moderate to severe atopic dermatitis...
news
Black Swan Analysis has added to its Epiomic Epidemiology series of reports with Atopic Dermatitis forecast in 17 major markets 2015-2025
1 December 2015 | By Black Swan Analysis
Research and Markets has announced the addition of the "Epiomic Epidemiology Series: Atopic Dermatitis Forecast in 17 Major Markets 2015-2025" report to their offering...
news
Atopic dermatitis treatment market to more than double in value
19 November 2015 | By Victoria White
The global atopic dermatitis treatment market will more than double in value from $3.6 billion in 2014 to an estimated $7.3 billion by 2024, according to research and consulting firm GlobalData.
news
Researchers beat untreatable eczema with arthritis drug
20 July 2015 | By Victoria White
Researchers have successfully treated patients with moderate to severe eczema using an arthritis drug recently shown to reverse two other skin conditions...
news
Anacor’s crisaborole achieves primary and secondary endpoints in two Phase 3 studies in eczema
13 July 2015 | By Victoria White
Anacor has announced positive preliminary top-line results from its two Phase 3 pivotal studies of crisaborole in atopic dermatitis (eczema)...
news
US sales of Sanofi/Regeneron’s Dupilumab for atopic dermatitis could exceed $1.3 Billion by 2022, says GlobalData Analyst
4 December 2014 | By GlobalData
The first biologic to treat atopic dermatitis, Sanofi and Regeneron’s dupilumab, could launch in the US by Q2 2017, and the potentially game-changing drug could achieve annual sales of over $1.3 billion in this market by 2022, according to an analyst with research and consulting firm GlobalData.
news
Sanofi and Regeneron announce positive results from Phase 2b study of Dupilumab in patients with moderate-to-severe atopic dermatitis
10 July 2014 | By Sanofi
Sanofi (EURONEXT : SAN and NYSE : SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive results from a Phase 2b dose-ranging study of dupilumab, an investigational therapy, in adult patients with moderate-to-severe atopic dermatitis (AD), a serious, chronic form of eczema.
news
Sanofi and Regeneron’s Dupilumab named “Clinical Advance of the Year” by Scrip Intelligence
25 November 2013 | By Sanofi
Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the Phase 2a study of dupilumab in asthma was named "Clinical Advance of the Year" by Scrip Intelligence at the 9th annual Scrip Awards. The award was announced last week by Scrip, a leading pharmaceutical…
news
Sanofi and Regeneron report positive proof-of-concept data for Dupilumab
2 March 2013 | By Sanofi
Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that pooled data from two Phase 1b trials with dupilumab (REGN668/SAR231893), an investigational, high-affinity, subcutaneously administered, fully-human antibody targeting the alpha subunit of the interleukin 4 receptor (IL-4R alpha), were presented at the 71st Annual Meeting…
